Rapid Micro Biosystems, Inc. (RPID) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ryan Rice

Good afternoon, everyone. My name is Ryan Rice. I’m an associate with the JPMorgan Healthcare Investment Banking team. Welcome to the session for Rapid Micro Biosystems. Presenting today, we have the President and CEO, Rob Spignesi; and also the CFO, Sean Wirtjes. As a reminder, the presentation will be roughly 25 minutes, followed by about 15 minutes of Q&A. So we please just ask that you hold your questions until the end. With that being said, I’ll turn it over to Rob so we can get started. Thank you.

Robert Spignesi
CEO, President & Director

Thanks, Ryan. Good morning, everyone. Again, I’m Rob Spignesi, CEO of Rapid Micro Biosystems and joined by our CFO, Sean Wirtjes. Thank you for joining this morning. So to get — for those online, our deck is available on our website under Investors. It won’t sequence automatically. So I’ll do our best to keep us all in sync.

So Slide 3, if we can dive right in and by way of background and context on our business, we’re focused on a critical part of the global pharmaceutical quality control infrastructure called Microbial quality control. So this is a regulated process mandated by the global regulators, and all pharmaceutical companies go through this process. It’s a high-volume testing process to ensure their products are free of microbial contamination, so think bacteria, fungi and other organisms to ultimately ensure their products are safe for patients.

The problem with the current methods used in most locations around the world is they hasn’t advanced, literally using the same slow